

# T cell lymphoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/T9F17CFD3299EN.html>

Date: May 2021

Pages: 200

Price: US\$ 2,500.00 (Single User License)

ID: T9F17CFD3299EN

## Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "T cell lymphoma - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in T cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### T cell lymphoma Understanding

#### T cell lymphoma: Overview

T-cell lymphomas represent a diverse group of non-Hodgkin lymphomas of mature T-cell origin that generally are associated with unfavorable prognosis. However, recent breakthroughs have allowed a better understanding of pathogenetic mechanisms of T-cell lymphomagenesis and uncovered molecular alterations that can be assessed using new biomarker approaches and can be specifically targeted with documented improvements in outcomes. A particularly promising area in which significant progress has been made is the role of epigenetic alterations, including dysregulation of DNA methylation and histone modifications, in T-cell lymphomagenesis.

T-cell lymphomas encompass a group of heterogeneous diseases accounting for less

than 10% of non-Hodgkin lymphomas. With the exception of ALK positive anaplastic large cell lymphoma, T-cell lymphomas also tend to be more clinically aggressive than their B-cell counterparts.

In spite of substantial advances in the treatment of lymphoma in general, the prognosis of patients with relapsed or treatment-refractory T-cell lymphoma remains poor, necessitating the development of novel approaches and therapies. Epigenetic dysregulation has a potential role in initiating and promoting a wide variety of malignancies and is observed in both B-cell and T-cell lymphomas.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence T cell lymphoma R&D. The therapies under development are focused on novel approaches for T cell lymphoma.

## T cell lymphoma Emerging Drugs Chapters

This segment of the T cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## T cell lymphoma Emerging Drugs

### SGX-301: Soligenix

SGX301 is a photodynamic therapy using synthetically manufactured hypericin in an ointment combined with visible fluorescent light. Hypericin is one of the most photoactive compounds known – it is easily activated with relatively low energy light. This makes it ideal for photodynamic therapy because it can be activated with fluorescent light, instead of UV A or UV B light, which are associated with increased cancer risks.

Synthetic hypericin, the active ingredient in SGX301, tends to accumulate in T-cells. Once the hypericin is in the T-cells, it can be activated by safe, visible fluorescent light. When synthetic hypericin is activated it creates oxygen radicals which subsequently

cause cellular toxicity, killing the targeted T-cells. It is currently in Phase III stage of development for Cutaneous T-cell lymphoma and is being developed by Soligenix.

#### SP-02: Solasia Pharma

SP-02 (Darinaparsin) is a novel mitochondrial-targeted agent (organic arsenic) being developed for the treatment of various hematologic and solid cancers. In a Phase II study in the U.S. Intravenous darinaparsin demonstrated evidence of clinical activity in malignant lymphoma, and in particular peripheral T-cell lymphoma (PTCL). Darinaparsin was granted Orphan Drug Designation in the U.S. and Europe as a treatment of PTCL and Solasia intends to seek similar status in Japan.

It is currently in Phase III stage of development for the treatment of peripheral T-cell lymphoma (PTCL) and is being developed by Solasia Pharma.

Further product details are provided in the report

#### T cell lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different T cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players working on T cell lymphoma

There are approx. 100+ key companies which are developing the T cell lymphoma. The companies which have their T cell lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Soligenix.

#### Phases

DelveInsight's report covers around 120+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

T cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

T cell lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses T cell lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T cell lymphoma drugs.

T cell lymphoma Report Insights

T cell lymphoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

T cell lymphoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Scenario and Emerging Therapies:

How many companies are developing T cell lymphoma drugs?

How many T cell lymphoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for T cell lymphoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the T cell lymphoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for T cell lymphoma and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Celgene

CSPC ZhongQi Pharmaceutical Technology

Jazz Pharmaceuticals

Genor Biopharma

Eisai

Soligenix

Elorac

Shanghai YingLi Pharmaceutical

ViGenCell

Daiichi Sankyo

Chia Tai Tianqing Pharmaceutical Group

BeiGene

Kura Oncology

Solasia Pharma

Innovent biologics

Nanjing Sanhome Pharmaceutical

Rhizen Pharmaceuticals SA

4SC AG

Precision Bioscience

Millennium Pharmaceuticals, Inc.

Innate Pharma

ImmuneOncia Therapeutics

HUYA Bioscience International

CerRx, Inc.

Shandong New Time Pharmaceutical Co., LTD

Verastem, Inc.

Janssen Research & Development

Celleron Therapeutics

CStone Pharmaceuticals

Viridian Therapeutics

Hebei Senlang Biotechnology Inc.

Galderma

Seagen

Bioniz Therapeutics

Almirall

Dizal Pharmaceuticals

Pfizer

Hoffmann-La Roche

Affimed GmbH

Sorrento Therapeutics

Merck Sharp & Dohme



Eli Lilly and Company

Bayer

Genzyme

Portola Pharmaceuticals

Onyx Pharmaceuticals

AstraZeneca

Astex Therapeutics

Yake Biotechnology Ltd.

Aileron Therapeutics

Akeso Pharmaceuticals, Inc.

Viracta

Otsuka Pharmaceutical

VelosBio

Trillium Therapeutics Inc.

Mundipharma-EDO GmbH

TG Therapeutics, Inc.

PersonGen BioTherapeutics (Suzhou) Co

Sorrento Therapeutics

Oncotartis

Myeloid Therapeutics

Bio-Path Holdings, Inc.

Legend Biotech

Immune Cell

Genzada Pharmaceuticals

Gracell

CRISPR Therapeutics

Corvus Pharmaceuticals, Inc.

Rafael Therapeutics

Antengene Corporation

Viridian Therapeutics

iCell Gene Therapeutics

Tessa Therapeutics

Boryung Pharmaceutical Co., Ltd

Bristol-Myers Squibb

Antengene Corporation

Amgen

ADC Therapeutics S.A.

Legend Biotech USA Inc

VidacPharma

Medc Biopharma

Scopus Biopharma

Almirall

Brickell Bio

AVM Biotechnology

Autolus

Applied Therapeutics

TetraLogic Pharmaceuticals

Moleculin Biotech

## Key Products

Lenalidomide

Mitoxantrone Hydrochloride

JZP-458

GB226

Denileukin diftitox

SGX 301

Naloxone Hydrochloride

YY-20394

VT-EBV-N

Valemetostat Tosylate

TQ-B3525

TQ-B3101

Tislelizumab

Tipifarnib

SP-02L

SP-02

Sintilimab

SHC014748M

SGN-35

RP6530

Resminostat

Pembrolizumab

PBCAR20

Nivolumab

MLN 9708

Letermovir

Lacutamab

IPH4102

IMC-001

HBI-8000

Fenretinide

F520

Duvelisib

DS-3201

Daratumumab

CXD 101

CS1001

Cobomarsen

CD7 CAR-T

CD11301

Brentuximab Vedotin

BNZ132-1-40

BNZ1

AZD4205

Azacytidine

Avelumab

Atezolizumab

AFM13

STI-3031

MK-3475

LY3039478

Durvalumab

Copanlisib

Clofarabine

Cerdulatinib (PRT062070)

carfilzomib

AZD5991

ASTX660

ALRN-6924

AUTO4

AK104

Nanatinostat + Valganciclovir

ASTX660

ARGX-110

VLS-101

TTI-621

Tinostamustine

TGR-1202

Temsirolimus

Sofusa anti-PD1

SEA-TGT

OT-82

MT-101

L-Bcl-2 antisense oligonucleotide

LB1901

ICAR30 T cells

GZ17-6.02

GC027

CTX130

CPI-818

CPI-613/Devimistat

Cobomarsen

CD4 CAR T cells

CD30.CAR-T

BR101801

BMS-906024

AZD4573

ATG-010

AMG 319

ADCT-301

LB1901

CD7-CART

VDA-1102

MDC 2021

MDC 2020

CO-sTiRNA

CD-7 UCART

BNZ1

BBI-3000

AVM-0703

Auto 5

AT-104

Lorlatinib

CPX-351

SHP-141

WP1220



## Contents

Introduction

Executive Summary

T cell lymphoma: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

T cell lymphoma– DelveInsight's Analytical Perspective

In-depth Commercial Assessment

T cell lymphoma companies' collaborations, Licensing, Acquisition -Deal Value Trends

T cell lymphoma Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

SGX-301: Soligenix

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

AFM13: Affimed

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

MT-101: Myeloid Therapeutics

- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report.....
- Preclinical and Discovery Stage Products
  - Comparative Analysis
- AT-104: Applied Therapeutics
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Inactive Products
  - Comparative Analysis
- T cell lymphoma Key Companies
- T cell lymphoma Key Products
- T cell lymphoma- Unmet Needs
- T cell lymphoma- Market Drivers and Barriers
- T cell lymphoma- Future Perspectives and Conclusion
- T cell lymphoma Analyst Views
- T cell lymphoma Key Companies
- Appendix

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for T cell lymphoma
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for T cell lymphoma
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: T cell lymphoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/T9F17CFD3299EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T9F17CFD3299EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970